Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Respiratory IL-5 Coverage | OpenP…
    Ask Trek AI about this page
    ModifiedUnitedHealthcarePolicy 2026D0055AA

    Respiratory Interleukin-5 Inhibitor

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy 2026D0055AA alerts

    Get alerted when Policy 2026D0055AA changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs UnitedHealthcare Commercial and Individual Exchange coverage and prior authorization for provider-administered Cinqair, Exdensur, Fasenra, and Nucala used for eosinophilic granulomatosis with polyangiitis or severe eosinophilic asthma. It also specifies benefit routing, authorization duration, prescriber requirements, combination-therapy exclusions, and continuation criteria.

    Policy Summary
    PayerUnitedHealthcare
    PolicyRespiratory Interleukin-5 Inhibitor
    Policy CodePolicy 2026D0055AA
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for provider-administered therapy and limit initial authorization to no more than 12 months.
    SourceLink
    POLICY UPDATE CHANGES

    Exdensur (depemokimab-ulaa) was added to the applicable provider-administered drug products for subcutaneous administration.

    Exdensur was designated proven and medically necessary for add-on maintenance treatment of severe asthma with an eosinophilic phenotype when the policy criteria are met.

    Fasenra administered by a provider was designated proven and medically necessary for hypereosinophilic syndrome lasting at least 6 months without an identifiable non-hematologic secondary cause when the policy criteria are met.

    Nucala coverage for provider-administered COPD was revised to require inadequately controlled COPD with an eosinophilic phenotype.

    The policy updated the list of anti-interleukin-5 therapies that must not be used in combination with Cinqair, Fasenra, Nucala, or Exdensur.

    The Cinqair eosinophilic-phenotype criterion was revised to use a baseline pre-treatment peripheral-blood eosinophil level of at least 150 cells per microliter.

    Combination-therapy requirements were removed for Nucala coverage for chronic rhinosinusitis with nasal polyps and COPD.

    The policy revised the chronic rhinosinusitis with nasal polyps criterion to require Nucala as add-on maintenance therapy and an inadequate response to nasal corticosteroids.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4Drug products addressed
    12 monthsMaximum authorization period
    ≥150 cells/μLAsthma eosinophil threshold
    ≥1000 cells/μLHES eosinophil threshold
    ≥6 monthsHES duration
    5 conditionsUnproven uses

    Medical Necessity and Coverage Criteria

    Fasenra EGPA initial therapy

    Covered for initial therapy when all of the following are met.

    Fasenra EGPA initial therapy: Relapsing or refractory EGPA, including EGPA diagnosis, asthma history or presence, at least two characteristic EGPA features, and qualifying relapsing or refractory disease; current standard therapy; no prohibited same-indication biologic combination; FDA-approved-label dosing; prescription by a pulmonologist, rheumatologist, or allergist/immunologist; and initial authorization no more than 12 months.

    Fasenra EGPA continuation

    Covered for continuation when all of the following are met.

    Fasenra EGPA continuation: Document positive clinical response; do not use Fasenra with another biologic class listed for the same indication; use FDA-approved-label dosing; and limit reauthorization to no more than 12 months.

    Positive response may include reduced relapse frequency or severity, reduced or discontinued corticosteroid or immunosuppressant doses, disease remission, or reduced EGPA symptom severity or frequency.

    Nucala EGPA initial therapy

    Covered for initial therapy when all of the following are met.

    Nucala EGPA initial therapy: Relapsing or refractory EGPA, including EGPA diagnosis, asthma history or presence, at least two characteristic EGPA features, and qualifying relapsing or refractory disease; current standard therapy; no prohibited same-indication biologic combination; FDA-approved-label dosing; prescription by a pulmonologist, rheumatologist, or allergist/immunologist; and initial authorization no more than 12 months.

    Nucala EGPA continuation

    Covered for continuation when all of the following are met.

    Nucala EGPA continuation: Document positive clinical response; do not use Nucala with another biologic class listed for the same indication; use FDA-approved-label dosing; and limit reauthorization to no more than 12 months.

    Positive response may include reduced relapse frequency or severity, reduced or discontinued corticosteroid or immunosuppressant doses, disease remission, or reduced EGPA symptom severity or frequency.

    Cinqair severe asthma initial therapy

    Covered for initial therapy when all of the following are met.

    • Controller therapy: Use either one maximally dosed ICS/LABA product or a maximally dosed ICS product plus one additional asthma controller medication.
    • Step therapy

      • Fasenra/Nucala prerequisite: Failure of a four-month Fasenra or Nucala trial, or contraindication or intolerance to both.4 months
      • Tezspire prerequisite: Failure of a four-month Tezspire trial, or contraindication or intolerance to Tezspire.4 months

    Cinqair severe asthma continuation

    Covered for continuation when all of the following are met.

    Cinqair severe asthma continuation: Document positive clinical response; use with an ICS-containing maintenance medication; meet the required Fasenra or Nucala and Tezspire step-therapy or contraindication/intolerance criteria; do not use Cinqair with another listed biologic for the same indication; use FDA-approved-label dosing; and limit reauthorization to no more than 12 months.

    Fasenra severe asthma initial therapy

    Covered for initial therapy when all of the following are met.

    • Controller therapy: Use either one maximally dosed ICS/LABA product or a maximally dosed ICS product plus one additional asthma controller medication.

    Fasenra severe asthma continuation

    Covered for continuation when all of the following are met.

    Fasenra severe asthma continuation: Document positive clinical response; use with an ICS-containing maintenance medication; do not use Fasenra with another listed biologic for the same indication; use FDA-approved-label dosing; and limit reauthorization to no more than 12 months.

    Nucala chronic rhinosinusitis with nasal polyps

    Covered when all diagnostic and prior-treatment criteria are met.

    CRSwNP diagnosis and prior treatment: CRSwNP with at least two qualifying symptoms lasting more than 12 weeks; objective nasal endoscopy or sinus CT findings; bilateral nasal polyposis or prior bilateral polyp removal; and prior sinus surgery, systemic corticosteroids within the previous 2 years, or inadequate response to required medical therapy.≥2 symptoms for >12 weeks

    Nucala for CRSwNP

    Covered for initial therapy when all of the following are met.

    Nucala CRSwNP initial therapy: Qualifying CRSwNP symptoms for more than 12 weeks; objective nasal endoscopy or sinus CT findings; bilateral polyposis or prior bilateral polyp removal; prior sinus surgery, systemic corticosteroid use within the previous 2 years, or inadequate response to two specified agent classes; add-on maintenance therapy with intranasal corticosteroids; no prohibited same-indication biologic combination; FDA-label-concordant dosing; specialist prescribing; and authorization no more than 12 months.Symptoms >12 weeks

    Nucala CRSwNP continuation

    Covered for continuation when all of the following are met.

    Nucala CRSwNP continuation: Document positive clinical response; continue add-on maintenance therapy with intranasal corticosteroids; avoid prohibited same-indication biologic therapy; use FDA-label-concordant dosing; and limit reauthorization to no more than 12 months.

    Nucala for COPD

    Covered for initial therapy when all of the following are met.

    Nucala COPD initial therapy

    • Maintenance regimen: Triple LAMA/LABA/ICS therapy, or dual LAMA/LABA therapy with failure, contraindication, or intolerance to an ICS.

    Unproven indications

    The following uses are unproven and not medically necessary.

    Unproven uses: Acute bronchospasm; granulomatosis with polyangiitis (Wegener’s); microscopic polyangiitis; organ- or life-threatening EGPA; other eosinophilic conditions; status asthmaticus; or COPD when treated with Cinqair, Exdensur, or Fasenra.

    Exdensur severe eosinophilic asthma update

    Exdensur is proven and medically necessary when the policy criteria are met.

    Severe eosinophilic asthma: Severe asthma with an eosinophilic phenotype treated with Exdensur as add-on maintenance therapy.

    Fasenra hypereosinophilic syndrome update

    Provider-administered Fasenra is proven and medically necessary when the policy criteria are met.

    Hypereosinophilic syndrome lasting at least 6 months without an identifiable non-hematologic secondary cause.≥6 months

    Exdensur unproven uses

    Exdensur is unproven and not medically necessary for any of the following requested uses.

    Unproven Exdensur conditions: Acute bronchospasm; COPD; granulomatosis with polyangiitis (Wegener’s); microscopic polyangiitis; organ- or life-threatening EGPA; other eosinophilic conditions; or status asthmaticus.

    Exdensur (depemokimab-ulaa) is typically excluded from coverage. A coverage review may be available when required by law or the member’s benefit plan; consult the applicable excluded-drug policy and list with preferred alternatives.

    Coverage requires that the requested biologic not be used with another biologic or targeted therapy for the same indication, including an anti-interleukin-5, anti-IgE, anti-interleukin-4, or TSLP inhibitor.

    For Nucala treatment of HES, coverage is excluded when there is an identifiable non-hematologic secondary cause, such as drug hypersensitivity, parasitic helminth infection, HIV infection, or non-hematologic malignancy, or when the HES is FIP1L1-PDGFRα kinase-positive.

    The policy considers treatment of acute bronchospasm, granulomatosis with polyangiitis (Wegener’s), microscopic polyangiitis, organ- or life-threatening EGPA, other eosinophilic conditions, and status asthmaticus unproven and not medically necessary for Cinqair, Exdensur, Fasenra, and Nucala.

    COPD is unproven and not medically necessary when treatment is requested with Cinqair, Exdensur, or Fasenra.

    The HES clinical trial excluded patients with non-hematologic secondary HES, including drug hypersensitivity, parasitic helminth infection, HIV infection, or non-hematologic malignancy. It also excluded patients with FIP1L1-PDGFRα kinase-positive HES; these exclusions align with the policy’s HES coverage limitations.

    In the policy update, Exdensur (depemokimab-ulaa) was added as a provider-administered subcutaneous drug. It is typically excluded from coverage, although review may apply when required by law or the member’s benefit plan.

    Cinqair, Fasenra, Nucala, and Exdensur are not indicated for relief or treatment of acute bronchospasm or status asthmaticus. These drugs are intended for maintenance treatment within their applicable covered indications, not for acute respiratory rescue.

    The policy considers the following uses unproven and not medically necessary: acute bronchospasm, granulomatosis with polyangiitis, microscopic polyangiitis, organ- or life-threatening EGPA, other eosinophilic conditions, status asthmaticus, and COPD when treated with Cinqair, Exdensur, or Fasenra.

    Exdensur is unproven and not medically necessary when requested for acute bronchospasm, status asthmaticus, COPD, granulomatosis with polyangiitis (Wegener’s), microscopic polyangiitis, organ- or life-threatening EGPA, or other eosinophilic conditions.

    Initial Authorization Criteria

    Fasenra EGPA initial therapy

    Covered for initial therapy when all of the following are met.

    Fasenra EGPA initial therapy: Relapsing or refractory EGPA with EGPA diagnosis, asthma history or presence, at least two characteristic EGPA features, qualifying relapsing or refractory disease, current standard therapy, no prohibited combination, FDA-label dosing, qualified specialist prescribing, and authorization no more than 12 months.

    Nucala EGPA initial therapy

    Covered for initial therapy when all of the following are met.

    Nucala EGPA initial therapy: Relapsing or refractory EGPA with EGPA diagnosis, asthma history or presence, at least two characteristic EGPA features, qualifying relapsing or refractory disease, current standard therapy, no prohibited combination, FDA-label dosing, qualified specialist prescribing, and authorization no more than 12 months.

    Cinqair severe asthma initial therapy

    Continuation and Reauthorization Criteria

    Fasenra EGPA continuation

    Covered for continuation when all of the following are met.

    Fasenra EGPA continuation: Document positive clinical response; no prohibited combination therapy; FDA-label dosing; and reauthorization no more than 12 months.

    Nucala EGPA continuation

    Covered for continuation when all of the following are met.

    Nucala EGPA continuation: Document positive clinical response; no prohibited combination therapy; FDA-label dosing; and reauthorization no more than 12 months.

    Cinqair severe asthma continuation

    Covered for continuation when all of the following are met.

    Required Prior Therapies

    Required prior therapyRequirement
    Fasenra or NucalaDocument failure of a 4-month trial, or contraindication or intolerance to both Fasenra and Nucala.
    TezspireDocument failure of a 4-month trial, or contraindication or intolerance to Tezspire.
    Required prior therapyRequirement
    Fasenra or NucalaDocument failure of a 4-month trial, or contraindication or intolerance to both Fasenra and Nucala.
    TezspireDocument failure of a 4-month trial, or contraindication or intolerance to Tezspire.
    Prior treatment pathwayRequirement
    Sinus surgery, systemic corticosteroids, or medical therapyDocument prior sinus surgery; systemic corticosteroid treatment for CRSwNP within the previous 2 years; or inability to obtain symptom relief after trials of two specified agent classes, including nasal saline irrigations.
    Qualifying maintenance regimenRequirement
    Triple therapy: LAMA/LABA/ICSCOPD exacerbations occurred despite triple therapy. Nucala must be used as add-on maintenance therapy with this regimen.
    Dual therapy: LAMA/LABA with ICS failure, contraindication, or intoleranceCOPD exacerbations occurred despite dual LAMA/LABA therapy and failure, contraindication, or intolerance to an ICS. Nucala must be used as add-on maintenance therapy with this regimen.

    Authorization Duration and Dosing Limits

    Authorization duration
    Initial authorizationNo more than 12 months
    ReauthorizationNo more than 12 months
    Applies toFasenra, Nucala, or Cinqair
    Authorization duration
    Initial authorizationNo more than 12 months
    ReauthorizationNo more than 12 months
    Applies toFasenra, Nucala, and Exdensur

    Coding and Clinical Thresholds

    HCPCS CodesHCPCS
    J0517Injection, benralizumab, 1 mg
    J2361Injection, depemokimab-ulaa, 1 mg
    J2786Injection, reslizumab, 1 mg
    Applicable Diagnosis CodesICD-10
    D72.11Hypereosinophilic Syndrome
    J31.0Chronic rhinitis
    J32.0Chronic maxillary sinusitis
    J32.1Chronic frontal sinusitis
    J32.2Chronic ethmoidal sinusitis
    J32.3Chronic sphenoidal sinusitis
    J32.4Chronic pansinusitis
    J32.8Other chronic sinusitis
    Applicable Diagnosis CodesICD-10
    J32.9Chronic sinusitis, unspecified
    J33.0Polyp of nasal cavity
    J33.1Polypoid sinus degeneration
    J33.8Other polyp of sinus
    J33.9Nasal polyp, unspecified
    J44.0Chronic obstructive pulmonary disease with (acute) lower respiratory infection
    J44.1Chronic obstructive pulmonary disease with (acute) exacerbation
    J44.9Chronic obstructive pulmonary disease, unspecified
    J45.50Severe persistent asthma, uncomplicated
    J45.51Severe persistent asthma with (acute) exacerbation
    1–10 of 16
    1/2
    Baseline eosinophil threshold
    Required level≥150 cells/μL
    MeasurementBaseline, pre-treatment peripheral blood eosinophil level
    UseDefines the eosinophilic asthma phenotype
    Systemic corticosteroid bursts
    Number of burstsTwo or more
    DurationAt least 3 days each
    Look-back period

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Fasenra for EGPA: Initial Authorization

    Obtain prior authorization for provider-administered Fasenra for EGPA. Initial approval requires documentation of relapsing or refractory EGPA, current standard therapy, appropriate dosing, eligible prescriber, and no prohibited combination therapy.

    • Diagnosis of EGPA, asthma history or presence, and at least two characteristic EGPA features.
    • Relapsing disease: at least one relapse within the past 2 years requiring additional or escalated corticosteroid/immunosuppressant therapy or hospitalization; or refractory disease: failure to attain remission within the prior 6 months after standard induction therapy.
    • Patient is currently receiving systemic glucocorticoid therapy with or without immunosuppressive therapy.
    • Initial authorization is limited to 12 months.
    Prior Authorization

    Nucala for EGPA: Initial Authorization

    Obtain prior authorization for provider-administered Nucala for EGPA. Initial approval requires the same relapsing or refractory EGPA documentation, current standard therapy, appropriate dosing, eligible prescriber, and no prohibited combination therapy.

    Administration Setting

    Billing Rule

    Use the specified administration route

    Cinqair is addressed for intravenous administration by a healthcare professional. Exdensur, Fasenra, and Nucala are addressed for subcutaneous administration by a healthcare professional.

    Billing Rule

    Route provider-administered drugs correctly

    The drugs addressed by this policy are provider-administered under the medical benefit. Self-administered Fasenra and Nucala are generally obtained under the pharmacy benefit unless the member’s benefit plan specifies otherwise.

    Billing Rule

    Bill provider-administered Nucala

    Clinical Definitions

    Relapsing or refractory EGPA
    Relapsing diseaseAt least one EGPA relapse within the past 2 years requiring additional or dose-escalated corticosteroids or immunosuppressant therapy, or hospitalization
    Refractory diseaseFailure to attain remission within the prior 6 months after induction with standard therapy
    Diagnosis contextEGPA with asthma history or presence and at least two characteristic features
    Uncontrolled or inadequately controlled asthma
    Poor symptom controlACQ consistently >1.5 or ACT consistently <20
    Utilization findingTwo or more systemic corticosteroid bursts of at least 3 days in the prior 12 months or asthma-related emergency treatment

    Policy Background

    This policy addresses provider-administered respiratory interleukin-5 pathway biologics used for eosinophilic inflammatory disease: Cinqair, Exdensur, Fasenra, and Nucala. Coverage focuses on relapsing or refractory EGPA, severe uncontrolled or inadequately controlled asthma with an eosinophilic phenotype, HES, CRSwNP, and—in the applicable Nucala criteria—inadequately controlled COPD with an eosinophilic phenotype. The policy also establishes prior authorization, benefit routing, authorization duration, specialist-prescriber, maintenance-therapy, combination-therapy, and continuation requirements.

    Policy Summary
    PayerUnitedHealthcare
    PolicyRespiratory Interleukin-5 Inhibitor
    Policy CodePolicy 2026D0055AA
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for provider-administered therapy and limit initial authorization to no more than 12 months.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaInitial Authorization CriteriaContinuation and Reauthorization CriteriaRequired Prior TherapiesAuthorization Duration and Dosing LimitsCoding and Clinical ThresholdsPrior Authorization and Documentation RequirementsAdministration SettingClinical DefinitionsPolicy Background

    Covered for initial therapy when all of the following are met.

    Cinqair severe asthma initial therapy: Severe uncontrolled or inadequately controlled eosinophilic asthma; baseline eosinophils at least 150 cells/μL; required controller therapy; required Fasenra or Nucala and Tezspire step therapy or applicable contraindication/intolerance; no prohibited combination; FDA-label dosing; qualified specialist prescribing; and authorization no more than 12 months.≥150 cells/μL

    Fasenra severe asthma initial therapy

    Covered for initial therapy when all of the following are met.

    Fasenra severe asthma initial therapy: Severe uncontrolled or inadequately controlled eosinophilic asthma; baseline eosinophils at least 150 cells/μL; required controller therapy; no prohibited combination; FDA-label dosing; qualified specialist prescribing; and authorization no more than 12 months.≥150 cells/μL

    Asthma biologic initial therapy

    Initial therapy requires all applicable criteria.

    Asthma biologic initial therapy: Severe asthma; uncontrolled or inadequately controlled disease; baseline eosinophilic phenotype; appropriate high-intensity inhaled maintenance therapy; no concurrent same-indication biologic; FDA-label dosing; appropriate specialist prescribing; and initial authorization no more than 12 months.Baseline eosinophils ≥150 cells/μL

    Exdensur additionally requires the specified prior biologic failures or contraindications/intolerances.

    HES biologic initial therapy

    Initial HES therapy requires all applicable criteria.

    HES biologic initial therapy: HES for at least 6 months; baseline eosinophils at least 1000 cells/μL within the prior 4 weeks; stable background HES therapy; no prohibited concurrent biologic; FDA-label dosing; and eligible specialist prescribing.HES ≥6 months; eosinophils ≥1000 cells/μL

    Nucala additionally requires no identifiable non-hematologic secondary cause and HES not to be FIP1L1-PDGFRα kinase-positive.

    Nucala CRSwNP initial therapy

    Covered for initial therapy when all of the following are met.

    Nucala CRSwNP initial therapy: Qualifying symptoms for more than 12 weeks; objective nasal endoscopy or sinus CT findings; bilateral polyposis or prior bilateral polyp removal; prior sinus surgery, systemic corticosteroid use within the previous 2 years, or inadequate response to two specified agent classes; add-on intranasal corticosteroid therapy; no prohibited combination; FDA-label dosing; specialist prescribing; and authorization no more than 12 months.

    Nucala COPD initial therapy

    Covered for initial therapy when all of the following are met.

    Nucala COPD initial therapy: COPD defined by post-bronchodilator FEV1/FVC less than 0.7 and FEV1 20%–80% predicted; eosinophils at least 300 cells/μL; uncontrolled or inadequately controlled disease with qualifying exacerbations; exacerbation despite triple or qualifying dual maintenance therapy; add-on use; no prohibited combination; FDA-label dosing; and authorization no more than 12 months.

    Initial biologic authorization

    Initial coverage requires all applicable indication-specific requirements.

    Initial biologic authorization: The requested provider-administered biologic is used for an indication designated proven by the policy, satisfies the applicable medical-necessity criteria, uses FDA-label-concordant dosing, is prescribed by the required specialist, and meets combination-therapy restrictions.
    Cinqair severe asthma continuation: Document positive clinical response; use with an ICS-containing maintenance medication; meet required step-therapy or contraindication/intolerance criteria; no prohibited combination; FDA-label dosing; and reauthorization no more than 12 months.

    Fasenra severe asthma continuation

    Covered for continuation when all of the following are met.

    Fasenra severe asthma continuation: Document positive clinical response; use with an ICS-containing maintenance medication; no prohibited combination; FDA-label dosing; and reauthorization no more than 12 months.

    Asthma biologic continuation

    For asthma indications, continuation requires all of the following.

    Asthma biologic continuation: Document positive clinical response; use with an ICS-containing maintenance medication; no concurrent same-indication anti-IL-5, anti-IgE, anti-IL-4, or TSLP inhibitor therapy; FDA-label dosing; and reauthorization no more than 12 months.

    HES biologic continuation

    For HES indications, continuation requires all of the following.

    HES biologic continuation: Document positive clinical response; no concurrent same-indication anti-IL-5, anti-IgE, anti-IL-4, or TSLP inhibitor therapy; FDA-label dosing; and reauthorization no more than 12 months.

    Nucala CRSwNP continuation

    For CRSwNP continuation, all of the following are required.

    Nucala CRSwNP continuation: Document positive clinical response; continue add-on maintenance therapy with intranasal corticosteroids; avoid prohibited same-indication biologic therapy; use FDA-label-concordant dosing; and reauthorization no more than 12 months.

    Nucala maintenance continuation

    For continuation, all of the following are required.

    Nucala maintenance continuation: Document positive clinical response; continue maintenance therapy; avoid concomitant anti-IL-5, anti-IgE, anti-IL-4, or TSLP inhibitor therapy for the same indication; use FDA-label-concordant dosing; and use specialist prescribing as applicable.
    Authorization duration
    Initial authorizationNo more than 12 months where specified
    ReauthorizationNo more than 12 months where specified
    DrugNucala
    Dosing frequency
    First 3 dosesOnce every 4 weeks
    Subsequent dosesOnce every 4 or 8 weeks
    DrugBenralizumab
    Dosing frequency
    FrequencyOnce every 4 weeks
    Route in cited studiesMepolizumab was administered as adjunct to existing background therapy
    DrugMepolizumab
    Dosing frequency
    Dose3 mg/kg
    FrequencyOnce every 4 weeks
    DrugReslizumab
    Dosing frequency
    Dose100 mg subcutaneously
    FrequencyOnce every 6 months
    Treatment periodTwo doses during the 52-week treatment period
    Dosing frequency
    Dose300 mg subcutaneously
    FrequencyOnce every 4 weeks
    IndicationHypereosinophilic syndrome
    Dosing frequency
    Dose100 mg subcutaneously
    FrequencyOnce every 4 weeks
    IndicationChronic rhinosinusitis with nasal polyps
    Previous 12 months
    ACQ symptom control score
    ThresholdConsistently greater than 1.5
    MeasureAsthma Control Questionnaire (ACQ) score
    RoleQualifying poor symptom control
    ACT symptom control score
    ThresholdConsistently less than 20
    MeasureAsthma Control Test (ACT) score
    RoleQualifying poor symptom control
    Airflow limitation
    FEV1Less than 80% predicted
    FEV1/FVCReduced below the lower limit of normal
    Testing conditionAfter appropriate bronchodilator withholding
    EGPA relapse history
    Relapse frequencyAt least one EGPA relapse
    Look-back periodWithin the past 2 years
    Qualifying eventRequires additional or dose-escalated corticosteroids or immunosuppressant therapy, or hospitalization
    EGPA refractory disease
    RequirementFailure to attain remission
    PeriodWithin the prior 6 months
    FollowingInduction treatment with standard therapy
    Asthma symptom control
    ACQ criterionConsistently >1.5
    ACT criterionConsistently <20
    LogicEither symptom-control criterion qualifies
    Systemic corticosteroid bursts
    Number of burstsTwo or more
    DurationAt least 3 days each
    Look-back periodPrevious 12 months
    Airflow limitation
    FEV1Less than 80% predicted
    FEV1/FVCReduced below the lower limit of normal
    Testing conditionAfter appropriate bronchodilator withholding
    Asthma eosinophil threshold
    Required level≥150 cells/μL
    MeasurementBaseline peripheral blood eosinophil level
    TimingPre-treatment
    HES duration
    Minimum duration≥6 months
    ConditionHypereosinophilic syndrome
    Additional Nucala requirementNo identifiable non-hematologic secondary cause and not FIP1L1-PDGFRα kinase-positive
    HES eosinophil threshold
    Required level≥1000 cells/μL
    TimingWithin the past 4 weeks
    MeasurementBaseline blood eosinophil level
    CRSwNP symptom duration
    Number of symptomsTwo or more qualifying symptoms
    Duration>12 weeks
    ExamplesNasal discharge, obstruction, facial pain or pressure, or reduced/lost sense of smell
    CRSwNP symptom duration
    Required durationLonger than 12 weeks
    ConditionChronic rhinosinusitis with nasal polyps
    Diagnostic supportQualifying symptoms with objective nasal endoscopy or sinus CT findings
    Post-bronchodilator FEV1/FVC
    Required ratio<0.7
    MeasurementPost-bronchodilator FEV1/FVC
    ConditionCOPD diagnostic criterion
    Post-bronchodilator FEV1
    Lower bound≥20% predicted
    Upper bound≤80% predicted
    MeasurementPost-bronchodilator FEV1 percent predicted
    COPD eosinophil threshold
    Required level≥300 cells/μL
    MeasurementBaseline peripheral blood eosinophils
    TimingBefore mepolizumab treatment
    COPD exacerbation history
    Alternative 1≥2 exacerbations in the previous year requiring systemic corticosteroids and/or antibiotics
    Alternative 2≥1 exacerbation resulting in hospitalization or observation over 24 hours
    Treatment contextExacerbations occurred despite qualifying maintenance therapy
    Adult anti-IL-5 initiation
    Cut-point≥150 μL−1
    PopulationAdult patients with severe asthma
    UseGuides anti-IL-5 initiation
    Anti-IgE response eosinophils
    Cut-off≥260 μL−1
    PopulationAdolescents or adults
    UseIdentifies patients most likely to respond to anti-IgE therapy
    Anti-IgE response exhaled nitric oxide
    Cut-off≥19.5 ppb
    MeasureExhaled nitric oxide fraction
    PopulationAdolescents or adults
    • Document EGPA, asthma history or presence, at least two characteristic EGPA features, and relapsing or refractory disease.
    • Patient is currently receiving systemic glucocorticoid therapy with or without immunosuppressive therapy.
    • Initial authorization is limited to 12 months.
    Prior Authorization

    Cinqair for Severe Asthma: Prior Authorization

    Cinqair requires prior authorization for severe eosinophilic asthma. Submit clinical documentation establishing uncontrolled or inadequately controlled severe asthma, eosinophilic phenotype, required controller therapy, prerequisite biologic trials, and an eligible prescriber.

    • Baseline pre-treatment peripheral blood eosinophils must be at least 150 cells/µL.
    • Use with a maximally dosed ICS/LABA or maximally dosed ICS plus an additional asthma controller.
    • Initial authorization is limited to 12 months; reauthorization is limited to 12 months.
    Prior Authorization

    Fasenra for Severe Asthma: Prior Authorization

    Fasenra requires prior authorization for provider-administered add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Submit documentation of disease severity, controller therapy, FDA-label dosing, eligible prescribing specialist, and absence of prohibited combination therapy.

    • Baseline pre-treatment peripheral blood eosinophils must be at least 150 cells/µL.
    • Use with a maximally dosed ICS/LABA or maximally dosed ICS plus an additional asthma controller.
    • Initial and reauthorization periods are limited to 12 months.
    Prior Authorization

    Initial Authorization Requirements

    For initial authorization, document the diagnosis-specific medical-necessity requirements, current background or maintenance therapy, FDA-approved dosing, eligible prescriber, and the applicable authorization period.

    • Applies to initial therapy for severe asthma, EGPA, Exdensur severe asthma, and HES as applicable.
    • Include objective disease findings, required laboratory values, treatment history, and concurrent therapy details.
    Documentation Required

    Reauthorization Requirements

    For reauthorization, submit evidence that the member has benefited from therapy and continues to meet diagnosis-specific maintenance requirements. Reauthorization is generally limited to 12 months.

    • Document positive clinical response, continued required maintenance therapy, FDA-label dosing, and absence of prohibited combination therapy.
    • Response may include fewer exacerbations or flares, reduced rescue medication or background therapy, improved lung function, remission, or reduced disease symptoms.
    Prior Authorization

    Nucala: Initial Authorization

    For initial Nucala authorization, document the applicable diagnosis, required clinical findings, background or maintenance therapy, FDA-approved dosing, eligible prescriber, and absence of prohibited combination therapy.

    • Applies to CRSwNP, COPD, HES, and other covered Nucala indications as applicable.
    • Initial authorization is limited to 12 months.
    Documentation Required

    Nucala: Reauthorization

    For Nucala reauthorization, document positive response and continued use of the required maintenance therapy for the covered indication. Reauthorization is limited to 12 months.

    • CRSwNP requires continued intranasal corticosteroid therapy.
    • COPD requires continued maintenance therapy; HES requires maintained or reduced background therapy.
    • Continue to document FDA-label dosing and no prohibited combination therapy.
    Prior Authorization

    Prior Authorization Required

    Prior authorization is required before coverage review for Exdensur and the other provider-administered products addressed by this policy.

    • Verify the member-specific benefit and applicable plan requirements before requesting authorization.
    • Submit diagnosis, objective clinical findings, treatment history, dosing, and prescriber information.
    Step Therapy

    Required Biologic Trials Before Cinqair

    Before Cinqair is authorized for severe asthma, document either failure of a 4-month trial of Fasenra or Nucala, or contraindication/intolerance to both; and either failure of a 4-month trial of Tezspire, or contraindication/intolerance to Tezspire.

    • The Fasenra/Nucala requirement is one pathway: failure of a 4-month trial of either agent, or contraindication/intolerance to both.
    • The Tezspire requirement is separate and must also be satisfied.
    • For Medicare reviews, refer to the CMS section.
    Step Therapy

    Exdensur: Prerequisite Biologics

    Before Exdensur is authorized for severe asthma, document either failure of a 4-month trial of Fasenra or Nucala, or contraindication/intolerance to both; and either failure of a 4-month trial of Tezspire, or contraindication/intolerance to Tezspire.

    • Submit trial dates, response or failure details, and the reason for any contraindication or intolerance.
    • For Medicare reviews, refer to the CMS section.
    Documentation Required

    CRSwNP Diagnostic Documentation

    For CRSwNP, document at least two qualifying symptoms lasting longer than 12 weeks, objective endoscopic or sinus CT findings, and bilateral nasal polyposis or prior bilateral polyp removal.

    • Qualifying symptoms include mucopurulent discharge, nasal obstruction or congestion, facial pain/pressure/fullness, and reduced or lost sense of smell.
    • Objective findings include purulent mucus or edema, nasal or middle-meatus polyps, or sinus mucosal thickening/opacification.
    Documentation Required

    COPD Maintenance Therapy

    For Nucala in COPD, document maintenance therapy and the required exacerbation history before requesting authorization.

    • COPD must meet post-bronchodilator FEV1/FVC less than 0.7 and FEV1 20%–80% predicted.
    • Eosinophilic phenotype requires baseline pre-mepolizumab eosinophils of at least 300 cells/µL.
    • Exacerbations must occur despite triple LAMA/LABA/ICS therapy, or dual LAMA/LABA therapy with failure, contraindication, or intolerance to ICS.
    Documentation Required

    EGPA Initial-Therapy Documentation

    For initial EGPA therapy, submit records confirming the diagnosis and relapsing or refractory disease, including the required asthma history, characteristic disease features, relapse or refractory history, and current standard therapy.

    • Document at least two characteristic EGPA findings, such as eosinophilic tissue findings, neuropathy, pulmonary infiltrates, sinonasal disease, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, or ANCA positivity.
    • Document a qualifying relapse within 2 years or failure to attain remission within 6 months after standard induction therapy.
    • Document current systemic glucocorticoid therapy with or without immunosuppressive therapy.
    Documentation Required

    Continuation Documentation

    For continuation of Fasenra or Nucala for EGPA, document positive clinical response and continued FDA-label dosing. Confirm that the patient remains free of prohibited combination therapy.

    • Acceptable response includes fewer or less severe relapses, reduced or discontinued corticosteroid/immunosuppressant doses, remission, or reduced EGPA symptoms.
    • For asthma continuation, document reduced exacerbations, reduced rescue medication use, improved FEV1, or reduced asthma symptoms.
    • Reauthorization is limited to 12 months.
    Documentation Required

    Severe Asthma Clinical Documentation

    For severe asthma authorization, submit objective documentation of severe disease that is uncontrolled or inadequately controlled and has an eosinophilic phenotype.

    • Document poor symptom control, qualifying systemic steroid bursts, asthma-related emergency treatment, airflow limitation, or maintenance oral corticosteroid dependence.
    • Baseline pre-treatment eosinophils must be at least 150 cells/µL.
    • Document use of maximally dosed ICS/LABA or ICS plus an additional controller.
    Step Therapy

    Cinqair Step-Therapy Documentation

    Cinqair requires documentation of the applicable step-therapy pathway before initial or continued authorization.

    • Provide evidence of a 4-month Fasenra or Nucala trial failure, or contraindication/intolerance to both.
    • Provide evidence of a 4-month Tezspire trial failure, or contraindication/intolerance to Tezspire.
    Documentation Required

    HES Medical Records

    For Nucala or Fasenra treatment of HES, submit medical records establishing the duration, eosinophil level, background therapy, and exclusionary conditions.

    • Document HES for at least 6 months.
    • Submit chart notes and laboratory values showing baseline pre-treatment blood eosinophils of at least 1,000 cells/µL within the prior 4 weeks.
    • Document a stable dose of background HES therapy, such as an oral corticosteroid, immunosuppressor, or cytotoxic therapy.
    Documentation Required

    Continuation Response Documentation

    For continuation of covered therapy, document a positive clinical response and continued compliance with the indication-specific maintenance requirements.

    • Asthma response may include fewer exacerbations, less rescue medication, improved FEV1, or fewer symptoms.
    • EGPA response may include fewer relapses, reduced immunosuppression, remission, or fewer symptoms.
    • HES response may include fewer flares or maintained/reduced background therapy.
    Documentation Required

    Nucala Continuation and Prescribing Documentation

    For Nucala continuation, document positive response, the required concurrent maintenance therapy, FDA-label dosing, eligible prescriber, and no prohibited combination therapy.

    • For CRSwNP, continue intranasal corticosteroids.
    • For COPD, continue qualifying LAMA/LABA-based maintenance therapy.
    • For HES, document maintained or reduced background HES therapy.
    Documentation Required

    CRSwNP Diagnostic Documentation

    CRSwNP authorization requires documentation of the qualifying symptom duration, objective sinonasal findings, and bilateral disease or prior bilateral polyp surgery.

    • Symptoms must include at least two qualifying manifestations for more than 12 weeks.
    • Use nasal endoscopy and/or sinus CT to document objective disease.
    Documentation Required

    COPD Clinical Documentation

    For Nucala in COPD, document objective airflow obstruction, eosinophilic phenotype, inadequate control, qualifying exacerbations, and the maintenance regimen.

    • Post-bronchodilator FEV1/FVC must be less than 0.7 and FEV1 must be 20%–80% predicted.
    • Baseline pre-treatment eosinophils must be at least 300 cells/µL.
    • Document triple therapy or dual LAMA/LABA therapy with ICS failure, contraindication, or intolerance.

    Unsupported block type: documentation

    Denial Risk

    Exdensur Generally Excluded

    Exdensur is typically excluded from coverage. Coverage review may be available only when required by law or the member's benefit plan.

    • Check the member-specific benefit document and the excluded-drug list with preferred alternatives.
    • Do not assume that a clinical indication establishes coverage.
    Denial Risk

    Prohibited Combination Therapy

    Do not administer or authorize Fasenra, Nucala, Cinqair, or Exdensur in combination with another prohibited biologic for treatment of the same indication.

    • Prohibited classes include anti-IL-5 therapy, anti-IgE therapy, anti-IL-4 therapy, and TSLP inhibitors.
    • Examples include Cinqair, Exdensur, Fasenra, Nucala, Xolair, Dupixent, and Tezspire, as applicable to the requested product.
    Documentation Required

    Labeling and Prescriber Requirements

    Verify that the requested product is dosed according to FDA-approved labeling and prescribed by the required specialty before submitting or renewing authorization.

    • EGPA Fasenra and Nucala: pulmonologist, rheumatologist, or allergist/immunologist.
    • Severe asthma Fasenra and Cinqair: pulmonologist or allergist/immunologist.
    • Use the indication-specific specialty requirements for HES, CRSwNP, COPD, and Exdensur.
    Denial Risk

    HES Exclusionary Conditions

    HES coverage requires exclusion of identifiable non-hematologic secondary causes and FIP1L1-PDGFRα kinase-positive disease.

    • Exclude drug hypersensitivity, parasitic helminth infection, HIV infection, and non-hematologic malignancy.
    • HES must have persisted for at least 6 months.
    • Document the exclusion findings in the submitted medical records.
    Denial Risk

    Concurrent Biologic Therapy

    Concurrent biologic therapy for the same indication is not covered when it combines the requested agent with another anti-IL-5, anti-IgE, anti-IL-4, or TSLP biologic.

    • Review the complete medication list before authorization and reauthorization.
    • Document discontinuation or absence of overlapping biologic therapy.
    Step Therapy

    Required Prior Biologic Therapy for Exdensur

    Exdensur severe-asthma authorization requires the specified prerequisite biologic therapy documentation and no concurrent prohibited biologic.

    • Document failure of a 4-month Fasenra or Nucala trial, or contraindication/intolerance to both.
    • Document failure of a 4-month Tezspire trial, or contraindication/intolerance to Tezspire.
    • Do not combine Exdensur with Cinqair, Fasenra, Nucala, Xolair, Dupixent, or Tezspire for the same indication.
    Denial Risk

    HES Exclusion Criteria

    HES coverage is not supported when a non-hematologic secondary cause is identifiable or when the disease is FIP1L1-PDGFRα kinase-positive.

    • Examples of exclusionary secondary causes include drug hypersensitivity, parasitic helminth infection, HIV infection, and non-hematologic malignancy.
    • Do not submit HES authorization without documentation addressing these exclusions.
    Denial Risk

    Unproven Indications

    Cinqair, Exdensur, Fasenra, and Nucala are unproven and not medically necessary for listed unproven uses.

    • Acute bronchospasm, granulomatosis with polyangiitis, microscopic polyangiitis, organ- or life-threatening EGPA, other eosinophilic conditions, and status asthmaticus.
    • Cinqair, Exdensur, and Fasenra are also unproven for COPD.
    Denial Risk

    Nucala: Prohibited Combination Therapy

    Nucala must not be used with another biologic directed at the same indication, including another anti-IL-5 agent, anti-IgE therapy, anti-IL-4 therapy, or a TSLP inhibitor.

    • Review concurrent medications at initial authorization and reauthorization.
    • For COPD, also follow the indication-specific maintenance regimen requirements.
    Denial Risk

    HES Exclusion Criteria

    For HES-related Nucala authorization, verify and document that the HES exclusion criteria are satisfied before treatment.

    • Exclude identifiable non-hematologic secondary causes.
    • Confirm that HES is not FIP1L1-PDGFRα kinase-positive.
    Denial Risk

    Unproven Exdensur Uses

    Exdensur is unproven and not medically necessary for several listed uses, including conditions outside the covered severe-asthma indication.

    • Unproven uses include acute bronchospasm, COPD, granulomatosis with polyangiitis, microscopic polyangiitis, organ- or life-threatening EGPA, other eosinophilic conditions, and status asthmaticus.
    • FDA label inclusion or additional listed uses do not establish coverage.
    Denial Risk

    FDA Approval Is Not Sufficient

    FDA approval alone is not sufficient to establish coverage under this policy. Apply the member-specific benefit document and all policy medical-necessity criteria.

    • Confirm applicable federal or state mandates and plan terms.
    • Submit objective clinical documentation supporting the requested indication and treatment requirements.
    Denial Risk

    Exclusions and Prohibited Combination Therapy

    Coverage may be denied for excluded or unproven uses, prohibited combination therapy, or failure to meet the applicable prerequisite and documentation requirements.

    • Exdensur is typically excluded unless coverage review is required by law or the benefit plan.
    • Do not combine the requested biologic with another prohibited biologic for the same indication.
    • Verify the member-specific plan document before rendering or billing provider-administered therapy.

    Nucala for the covered indications described in this policy is administered by a provider under the medical benefit.

    Note

    Apply study administration details carefully

    The cited clinical studies administered the biologics subcutaneously, except reslizumab, which was administered at a weight-based dose. The cited study descriptions do not specify a required place of service.

    Other qualifying findingsAirflow limitation or maintenance oral corticosteroid dependence
    Eosinophilic asthma phenotype
    Required eosinophil levelBaseline, pre-treatment peripheral blood eosinophils ≥150 cells/μL
    DiseaseAsthma
    RoleDefines the eosinophilic phenotype
    Eosinophilic phenotype
    Required eosinophil levelBaseline, pre-treatment peripheral blood eosinophils ≥150 cells/μL
    DiseaseSevere asthma
    UseSupports selection of asthma biologic therapy
    Hypereosinophilic syndrome
    DurationDiagnosed for at least 6 months
    ExclusionNo identifiable non-hematologic secondary cause
    Nucala-specific exclusionNot FIP1L1-PDGFRα kinase-positive
    Chronic rhinosinusitis with nasal polyps
    SymptomsAt least two qualifying symptoms lasting longer than 12 weeks
    Objective findingsNasal endoscopy or sinus CT findings
    Polyp findingBilateral nasal polyposis or prior bilateral nasal polyp removal
    CRSwNP
    Duration12 weeks or longer
    SymptomsQualifying CRSwNP symptoms
    ConfirmationObjective endoscopic or CT findings
    COPD
    FEV1/FVCPost-bronchodilator ratio <0.7
    FEV1Post-bronchodilator FEV1 from 20% through 80% predicted
    Policy contextNucala is addressed for inadequately controlled COPD with an eosinophilic phenotype
    Eosinophilic phenotype
    Required eosinophil levelBaseline peripheral blood eosinophils ≥300 cells/μL
    TimingBefore mepolizumab treatment
    DiseaseCOPD
    Hypereosinophilic syndrome (HES)
    Core featureSustained overproduction of eosinophils
    Clinical effectTissue infiltration with organ damage
    Typical level and durationGenerally more than 1,500 eosinophils/μL for 6 months or longer when no cause is identified
    Uncontrolled asthma
    Symptom controlPoor symptom control, including frequent symptoms or reliever use, activity limitation, or night waking
    Frequent exacerbationsAt least 2 per year requiring oral corticosteroids
    Serious exacerbationsAt least 1 per year requiring hospitalization
    Difficult-to-treat asthma
    Persistent diseaseRemains uncontrolled despite medium- or high-dose inhaled corticosteroids with a second controller or maintenance oral corticosteroids
    Alternative descriptionRequires high-dose treatment to maintain control and reduce exacerbation risk
    Common second controllerUsually a long-acting beta agonist
    Severe asthma
    Treatment requirementMaximally optimized high-dose inhaled corticosteroid/long-acting beta agonist therapy
    Disease statusAsthma remains uncontrolled despite adherence and management of contributory factors
    Severity qualificationNot severe if it markedly improves after addressing inhaler technique or adherence
    HES flare
    Clinical changePhysician-documented change in HES clinical signs or symptoms
    Corticosteroid criterionIncrease in maintenance oral corticosteroids by at least 10 mg per day for 5 days
    Other criteriaIncrease or addition of cytotoxic or immunosuppressive therapy, or two or more courses of blinded active oral corticosteroids
    Severe asthma
    Required therapyHigh-dose inhaled corticosteroids plus a second controller or systemic corticosteroids
    PurposePrevent progression to uncontrolled disease
    Alternative statusRemains uncontrolled despite that therapy
    Eosinophilic phenotype
    Inflammatory profileEosinophilic inflammation
    Blood markerPolicy cites blood eosinophil thresholds
    Additional markerExhaled nitric oxide may guide treatment selection